Symposium | Introduction to T-cell engagers and general mechanism of action

The Multiple Myeloma Hub virtual symposium held on March 11, 2024, “Current and future perspectives for bispecific antibodies in multiple myeloma: Learnings from 2023,” was chaired by Sagar Lonial and featured expert presentations from Naresh Bumma, Amrita Krishnan, and Sergio Giralt.

Lonial opened with a welcome and introduction to T-cell-engaging bispecific antibodies and their mechanisms of action in multiple myeloma (Figure 1). Lonial also discusses the expanding treatment options in relapsed/refractory disease (Figure 2), offering insight into the targets for bispecific antibody action and their expression on myeloma cells.

Figure 1. T-cell directed bispecific antibodies: Mechanism of action* 

c, fragment crystallizable region; FcRH5, Fc receptor-homolog 5; GPRC5D, G protein–coupled receptor class C group 5 member D; MM, multiple myeloma.
 *Adapted from Van de Donk N, et al.¹

Figure 2. Treatment options for relapsed/refractory disease in multiple myeloma* 

BsAb, bispecific antibody; IMiD, immunomodulatory agent; mAb, monoclonal antibody; MoA, mechanism of action; PI, proteosome inhibitor.
*Data from Bhatt, et al.² and Gahvari, et al.³

This independent medical activity was funded by Janssen and Bristol Myers Squibb. All content was developed independently by the faculty. The funders were allowed no influence on the content of this activity.